Experts Dissect Key Findings for Progressive Gastric and GEJ Cancers

Christin L. Melton, ELS
Published: Friday, Sep 20, 2019
Johanna C. Bendell, MD

Johanna C. Bendell, MD

Although chemotherapy combinations remain standard first-line therapy for advanced or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) cancer, strategies for progressive disease have shifted to include antiangiogenic agents and immunotherapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication